中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (1): 31-35.doi: 10.12144/zgmfskin202401031

• 临床研究 • 上一篇    下一篇

巴瑞替尼治疗新冠疫苗接种后弥漫性斑秃一例

李筱娴1，2,李建可1，2,王秀环1，2,刘鑫洲1，2,刘国艳1，2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022; 2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2024-01-15 发布日期:2023-12-25

Diffuse alopecia areata after COVID-19 vaccine treated with baricitinib: a case report

LI Xiaoxian1，2, LI Jianke1，2, WANG Xiuhuan1，2, LIU Xinzhou1，2, LIU Guoyan1，2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-01-15 Published:2023-12-25

PDF (PC)

105

摘要： 本文报道一例巴瑞替尼成功治疗新冠疫苗接种后发生弥漫性斑秃的患者，给予巴瑞替尼每日4 mg，治疗6个月后停药，新生白色短发，停药1个月后，白发转为黑发。停药后随访10个月，至今仍未复发。

关键词: 新冠疫苗, 斑秃, 巴瑞替尼

Abstract: We report a patient with diffuse alopecia areata after COVID-19 vaccination who successfully treated with baratinib 4 mg daily. After 6 months of treatment, the drug was stopped, and the white hair turned to black hair 1 month after the drug was stopped. The patient was followed up for 10 months after drug withdrawal, and there was no recurrence.

Key words: COVID-19 vaccine, alopecia areata, baricitinib